Dive Brief:

简报：

Parabilis Medicines, formerly known as FogPharma, raised $305 million in a Series F financing to support its mission of pursuing disease targets long dismissed as out of reach by modern science.

Parabilis医药公司，前身为FogPharma，完成了3.05亿美元的F轮融资，以支持其追求现代科学长期以来认为无法触及的疾病靶点的使命。

RA Capital Management, Fidelity Management and Janus Henderson Investors led the latest round of financing, which included both old and new investors, Parabilis

RA资本管理、富达管理和詹纳斯亨德森投资者领投了最新一轮融资，参与的有老投资者也有新投资者，Parabilis。

said Thursday

周四表示

. The Series F gave the company a higher valuation

F轮融资使公司的估值更高。

than the previous round

比上一轮

, which pulled in $145 million in early 2024.

，这家公司在2024年初获得了1.45亿美元的收入。

The company plans to use the funds to advance its lead drug candidate, zolucatetide, which is designed to target a beta-catenin pathway connected to millions of cancer cases. The experimental therapy has shown “compelling preliminary data” in an ongoing Phase 1/2 trial, Parabilis said.

公司计划利用这笔资金推进其主要候选药物 zolucatetide 的研发，该药物旨在靶向与数百万癌症病例相关的 β-连环蛋白通路。Parabilis 表示，这种实验性疗法在正在进行的 1/2 期试验中展现了“令人信服的初步数据”。

Dive Insight:

深入洞察：

Parabilis is riding a wave of resurgent enthusiasm for venture capital funding in the industry. A downturn after the pandemic dramatically slowed the pace of new public offerings and left private companies struggling for cash. Trump administration policies that gutted scientific funding, introduced turmoil into regulatory agencies and threatened tariffs on the industry .

帕拉比里斯公司正乘着行业风险资本融资重新燃起的热情浪潮。疫情后的低迷期极大地减缓了新股发行的速度，使私营公司陷入资金困境。特朗普政府的政策削减了科学经费，给监管机构带来了混乱，并威胁要对征收该行业的关税。

made the situation worse

使情况变得更糟

.

。

But the second half of 2025 saw a turnaround for biopharma. Venture capital funding

但是，2025年下半年生物制药业出现了转机。风险资本 funding

rebounded

反弹

as concerns about tariffs

关于关税的担忧

lessened

减轻了

, key drug launches

，关键药物发布

beat expectations

超出预期

and a

和一个

flurry of acquisitions

收购狂潮

demonstrated faith in smaller biotechs. IPOs may be poised to bounce back as well, with

对小型生物技术公司表现出信心。首次公开募股（IPO）也可能准备反弹，随着

Aktis Oncology

活性肿瘤学

set to be the first to test the waters this year.

准备在今年率先试水。

The funding round announced by Parabilis comes amid similar recent announcements from

帕拉比里斯宣布的这轮融资正值近期类似公告发布之际

Soley Therapeutics

索利治疗学

,

，

Diagonal Therapeutics

对角线疗法

,

，

EpiBiologics

依皮生物技术

and

和

Beacon Therapeutics

Beacon Therapeutics

, among others. Parabilis’ financing is the largest disclosed in early January.

，其中最大的一笔融资是在1月初披露的Parabilis融资。

Parabilis has long had a high profile for a cancer medicine startup. The company’s Helicon technology is based on work done by co-founder Greg Verdine and his team in a laboratory at Harvard University starting in the late 1990s. Verdine has since become a

Parabilis 作为一家癌症药物初创公司，一直以来备受关注。该公司的 Helicon 技术基于联合创始人 Greg Verdine 及其团队从 20 世纪 90 年代末开始在哈佛大学实验室中所做的研究。Verdine 从此成为了一名...

serial biotech entrepreneur.

连续生物技术企业家。

At Harvard, Verdine’s team set out to

在哈佛，维尔丁的团队着手

overcome the problem

克服问题

that traditional drugs have in reaching and binding to disease-causing proteins inside a cell. They developed short peptides in a specific helix shape that could enter cells and block disease targets. The result was what is now the Helicon platform, which Parabilis says it can use to reach multiple critical targets previously considered undruggable..

传统药物在进入细胞内并与致病蛋白结合方面存在困难。他们开发了特定螺旋形状的短肽，这些短肽能够进入细胞并阻断疾病靶点。其结果就是现在的Helicon平台，Parabilis称该平台可以用于触及多个以前被认为无法成药的关键靶点。

Verdine became the first CEO when the company began operating in 2016, and it has steadily progressed with financing from leading health-care investors. In 2023, the company recruited the former head of Johnson & Johnson’s research department,

2016年公司开始运营时，维尔丁成为了首位首席执行官，并且在领先的医疗保健投资者的融资支持下，公司稳步发展。2023年，公司聘请了前强生公司研发部门负责人。

Mathai Mammen

马泰·马曼

, to take over as its leader.

，接任其领导人职位。